Pharmalucence gets FDA approval for generic Cardiolite

07/20/2009 | Mass High Tech (Boston)

The FDA gave radiopharmaceutical supplier Pharmalucence the green light to develop and market a generic version of Lantheus Medical Imaging's Cardiolite, a diagnostic imaging agent for coronary artery disease. Pharmalucence's product, the Kit for the Preparation of Technetium Tc-99m Sestamibi Injection, is used for identifying myocardial ischemia and infarction.

View Full Article in:

Mass High Tech (Boston)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY